A Phase 2 interventional study of Alpelisib in PIK3CA-related Overgrowth Spectrum (PROS), sponsored by Novartis Pharmaceuticals. Active, not recruiting at 6 sites in 4 countries. Open to participants aged 2 Years to 100 Years. Per ClinicalTrials.gov, last updated 2026-10-14.
Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
This Phase II, multicenter, open-label study, preceded by a retrospective non-interventional period, is assessing the long-term safety and efficacy of alpelisib in pediatric and adult participants with PIK3CA-related overgrowth spectrum (PROS).
The study will enroll male and female participants aged 2 years or older who previously participated in the EPIK-P1 study (NCT04285723) and continued to receive alpelisib after the EPIK-P1 data cut-off date of 09 March 2020.
The study consists of an initial retrospective period followed by a prospective period.
The retrospective, non-interventional period began on 10 March 2020, one day after the EPIK-P1 data cut-off date, and ended the day before the participant received the first interventional dose of alpelisib in the prospective period. Safety and efficacy data collected during routine medical practice were longitudinally abstracted from participants' medical records.
The prospective, interventional period began on the day the participant received the first interventional dose of alpelisib. Safety and efficacy data are being collected according to a structured assessment plan common to all participants. The prospective period will end after all participants have completed at least 5 years of treatment or discontinued treatment earlier, whichever occurs first.
Novartis Pharmaceuticals is the lead sponsor of 2,719 studies on the registry; 222 are open to participants now.
Of its 585 completed or terminated interventional studies of FDA-regulated products, 439 (75%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
For participants in the retrospective period
- All EPIK-P1 participants who permanently discontinued the drug on or prior to the cut-off date 09-Mar-2020.
For participants in the prospective period
Previous alpelisib treatment discontinuation (after 09-Mar-2020) due to any of the following adverse events:
Other inclusion/exclusion criteria may apply
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
All participants receive alpelisib orally once daily during the prospective period. Treatment is planned for at least 5 years or until earlier discontinuation.
Drug: Alpelisib
Retrospective period: Participants receive alpelisib under a Temporary Authorization for Use (ATU) or Managed Access Program (MAP) according to the treatment plan established by the treating physician. The recommended starting dose is 50 mg orally once daily for pediatric participants and 250 mg orally once daily for adult participants. Pediatric treatment interruptions and adult dose adjustments are permitted for toxicity. Prospective period: Participants receive alpelisib orally once daily with food. The starting dose is generally based on the last dose received during the retrospective period. Participants transitioning from fasted to fed administration may start at an adjusted dose. Dose escalation for response optimization and dose reduction or interruption for safety or tolerability are permitted. Dose escalation above 250 mg is not allowed. Treatment is planned for at least 5 years or until earlier discontinuation.
Also known as: BYL719
Prospective period only: Proportion of participants with new or worsening grade ≥3 treatment emergent adverse events (AEs)
Incidence of new or worsening grade ≥3 treatment emergent AEs (by system organ class and preferred term)
Time frame: From first interventional dose administration in the prospective period (Day 1) until treatment discontinuation, assessed for at least 5 years; participants not entering a Novartis rollover study undergo a 30-day safety follow-up after the last dose.
Retrospective period: Proportion of participants with Adverse Events (AEs)
Incidence, type and severity per CTCAE v4.03 criteria, causality assessments of AEs, including changes in laboratory values, vital signs and cardiac function during the retrospective period.
Time frame: From 10-Mar-2020 (1 day after EPIK-P1 data cut-off date) to the day before the first interventional dose of alpelisib is administered in the prospective period (Day -1)
Prospective period: Proportion of participants with AEs
Incidence, type and severity per CTCAE v4.03 criteria, causality assessments of AEs, including changes in laboratory values, vital signs, cardiac function, and growth, sexual maturation, and bone/dental development (for applicable ages).
Time frame: From first interventional dose administration in the prospective period (Day 1) until treatment discontinuation, assessed for at least 5 years
Retrospective and prospective period: Overall clinical assessment as assessed by the investigator
Proportion of participants with overall clinical assessment reported as improvement, stable or worsened, as assessed by the investigator.
Time frame: Retrospective: From 10-Mar-2020 to Day -1. Prospective: From Day 1 until treatment discontinuation, assessed for at least 5 years.
Retrospective and prospective period: Incidence of PROS-related symptoms and complications/comorbidities among participants with symptoms and complications/comorbidities.
Incidence of symptoms and complications/comorbidities associated with PROS among affected participants.
Time frame: Retrospective: From 10-Mar-2020 to Day -1. Prospective: From Day 1 until treatment discontinuation, assessed for at least 5 years.
Retrospective and prospective period: Proportion of participants with healthcare visits/hospitalizations due to PROS.
Proportion of participants with healthcare visits/hospitalizations due to PROS.
Time frame: Retrospective: From 10-Mar-2020 to Day -1. Prospective: From Day 1 until treatment discontinuation, assessed for at least 5 years
Retrospective and prospective period: Proportion of participants requiring PROS-related treatment(s) other than alpelisib
Proportion of participants requiring PROS-related treatment(s) other than alpelisib, including medications (concomitant PROS-related medications including medication for the management of PROS related complications as well as medications to manage complications secondary to alpelisib) and non-drug treatments (e.g., feeding tube, ketogenic diet, non-invasive device for sleep apnea, sclerotherapy, endovascular occlusive procedures)
Time frame: Retrospective: From 10-Mar-2020 to Day -1. Prospective: From Day 1 until treatment discontinuation, assessed for at least 5 years
Retrospective and prospective period: Proportion of participants with dose adjustments of alpelisib
Proportion of participants requiring dose increase, reductions and interruptions of alpelisib
Time frame: Retrospective: From 10-Mar-2020 to Day -1. Prospective: From Day 1 until treatment discontinuation, assessed for at least 5 years
Retrospective and prospective period: Proportion of participants with PROS-related surgeries
Proportion of participants requiring surgery due to PROS
Time frame: Retrospective: From 10-Mar-2020 to Day -1. Prospective: From Day 1 until treatment discontinuation, assessed for at least 5 years
Plan to share: Yes — Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations. This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com
Started Jan 2022 (actual). Primary completion is estimated for Jun 2027, 64 months after the start.
Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 14, 2026: primary completion Aug 2027 → Jun 2027 and completion Aug 2027 → Jun 2027.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is active, not recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Alpelisib